Johnson & Johnson (NYSE:JNJ) is proving that it can successfully navigate patent-related headwinds through its newer medicines, while Danaher (NYSE:DHR) is betting on a recovery in life sciences and bioprocessing demand. Johnson & Johnson (NYSE:JNJ) is primarily dealing with product-specific and segment-level headwinds, whereas Danaher (NYSE:DHR) continues to face broader questions surrounding execution and the timing of a life sciences recovery. While Johnson & Johnson (NYSE:JNJ) expects these challenges to improve over time, investors may want to watch whether its MedTech business returns to its historical growth trajectory in the coming quarters. Some notable stakes for Johnson & Johnson (NYSE:JNJ) come from Fisher Asset Management, GQG Partners, and AQR Capital Management, with Balyasny Asset Management‘s position jumping by 1,411% to $146 million. Johnson & Johnson (NYSE:JNJ) appears to be benefiting from growing confidence in its pharmaceutical pipeline and raised guidance, while Danaher (NYSE:DHR) remains a longer-term recovery story that may require additional execution before institutional sentiment improves.